Online Pharmacy Medicine Blog

Today Israel drug maker Teva stated that it has received approval from the United States Food and Drug Administration to go ahead with production of generic antidepressant drug Effexor XR.

The drug originally produced by Wyeth has finally ran out of its exclusivity period, which means we will see a cheaper alternative on shelves beginning July 1.

Teva had sought approval for its generic drug in 2006, but under a patent settlement with Wyeth, the company agreed to hold off on selling the drug until now.

This is great news for those that pay for there prescriptions out of pocket. Generic versions will be drastically cheaper than there brand name counterparts. You can also expect to see the brand versions price drop due to the added competition.

Don’t wait any longer to save on your prescription medications sign up to ePharmacies.com today.

According to a report released today, U.S. employers can expect to see their health care costs rise by around 9 percent next year.
The South Florida Business Journal reports that

PricewaterhouseCoopers report predicted the continuation of several relevant trends in health care, namely the shifting of costs from employer to employee. As the premiums continue to increase and the effects of the recession drain businesses, more employers are requiring their employees to pay more for their benefits.

The PricewaterhouseCoopers report said that 42 percent of the employers surveyed plan to increase employee contributions for health insurance.

The PricewaterhouseCoopers report also found that:

* Sixty-seven percent of employers plan to expand or improve wellness programs
* More employers are dropping health benefits for retirees
* For the first time, the majority of U.S. workers are expected to have a deductible of $400 or more next year

Employers blame shifting of Medicare costs for much of the anticipated increase in their health care costs, the report found. It is yet to be seen how this will affect prescription medication coverage, but odds are it is not going to make it any cheaper.

If you are struggling to pay for your prescription drugs like Actos, Lexapro, Singulair, or Zocor, don’t wait around for the government or your employers help, take matters into your own hands today.

Order your prescription drugs from ePharmacies.com and start saving now!

Today AstraZeneca encountered a major setback in trying to extend the patent life of it blockbuster acid reflux drug Nexium. The patent was denied a patent extension by US regulators who did not see what the wanted when Astra tried to combine the drug with aspirin.

Loss of patent for Nexium and its 5 billion in yearly sales would be a big problem for AstraZeneca, who is trying to develop new drugs to fill the shoes of those who have lost patent protection in key markets.

According to ABC news,

The Anglo-Swedish drugmaker said it got a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its application to market Axanum, which combines aspirin with esomeprazole, the active ingredient in Nexium.

The delay for Axanum follows success with another Nexium line extension product, Vimovo, which won a green light from the FDA at the end of April. Vimovo, developed with Pozen, combines the anti-inflammatory drug naproxen and esomeprazole.

AstraZeneca faces another regulatory hurdle on Wednesday when an FDA expert panel meets to consider whether to approve its new infant lung drug motavizumab.

Winning over the panel may be tough, after FDA staff reported in briefing documents released last week that the drug carried a higher risk of causing severe allergic reactions than the company’s older product Synagis.

The loss of Nexium’s patent would definitely lower prices, as generic competition would not be far behind. One way or another, there is no reason sweat it’s approval, buy your drugs here at ePharmacies.com to save now!